Financings in Brief: Sonus Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
Sonus Pharmaceuticals: Commences initial public offering of 2.85 mil. shares to be sold at a price of $7 per share. Bothell, Washington-based Sonus previously expected to offer 2.5 mil. shares for $10 to $12 each ("The Gray Sheet" Oct. 2, p. 15). Underwriters Hambrecht & Quist, Montgomery Securities, and UBS Securities retain an over-allotment option to purchase up to 427,500 additional shares...
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.